ONI BioPharma Inc. Announces Closing on $2,600,000 in Equity Financing
June 13 2008 - 9:00AM
Marketwired
ALACHUA, FL (AMEX: ONI) today reported that it has closed on its
previously announced equity financing of $2,600,000. As a result of
the closing, the Company will issue 5,777,778 shares of common
stock and warrants to acquire 5,777,778 million shares of common
stock at an exercise price of $1.30 per share to the
purchasers.
Stanley B. Stein, the Company's President and CEO, stated, "We
are very pleased that we were able to close this expected financing
on a timely basis and obtain the approval from the American Stock
Exchange for the listing of the additional shares. With this
financing we are able to continue our commitment to deliver
shareholder value through the development and commercialization of
our products."
The securities described herein have not been registered under
the Securities Act in reliance on exemption from registration and,
as a result, the securities cannot be resold except pursuant to
registration under the Securities Act or an exemption.
About ONI BioPharma Inc.
ONI BioPharma Inc. is a biopharmaceutical company with a
pipeline of unique proprietary technologies. The Company has a
number of products in discovery, preclinical and clinical
development, with a concentration in the main therapeutic area of
infectious diseases. Our core pipeline includes products and
supporting platform technologies for use in the treatment and
diagnosis of human infections.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect ONI BioPharma Inc.'s current views with
respect to future events and financial performance. These
forward-looking statements are based on management's beliefs and
assumptions and information currently available. The words
"believe," "expect," "anticipate," "intend," "estimate," "project"
and similar expressions that do not relate solely to historical
matters identify forward-looking statements. Investors should be
cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors
that could cause actual results to differ materially from those
expressed in any such forward-looking statements. These factors
include, but are not limited to our ability to successfully develop
and commercialize our products and technologies and those set forth
in our most recently filed annual report on Form 10-KSB and
quarterly report on Form 10-Q, and other factors detailed from time
to time in filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update forward-looking
statements.
Contact: Oragenics, Inc. Stanley B. Stein 386-418-4018 X222
http://www.oragenics.com
Oragenics (AMEX:ONI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Oragenics (AMEX:ONI)
Historical Stock Chart
From Oct 2023 to Oct 2024